Abstract: An apparatus and a method for determining blood sugar based on heterogeneous spectrums are provided. The blood sugar model generation apparatus includes a data obtainer configured to obtain blood sugar profile data of a user based on a first type spectrum-blood sugar profile relationship model, a second type spectrum measurer configured to measure training second type spectrum data for the skin of the user, and a processor configured to generate an individualized blood sugar model based on the obtained blood sugar profile data and the measured training second type spectrum data.

Abstract: An optical measuring device including a light source, a light beam path adjuster, a light detector and a controller is provided. The light source may emit light toward an object in a predetermined progress direction. The light beam path adjuster may be disposed between the light source and the object and may change a progress path of the light emitted from the light source. The light detector may receive the light that is reflected from the object after passing through the light beam path adjuster. The controller may compare a first effective beam path length of the reflected light that the light detector receives with a predetermined target beam path length and control a refractive angle of the light beam path adjuster based on a beam path length difference between the first effective beam path length and the predetermined target beam path length.

Abstract: A disease prediction model construction apparatus is provided. The disease prediction model construction apparatus may include a spectral data acquisition unit that emits near-infrared rays toward a skin of a subject to acquire near-infrared spectral data and a prediction model construction unit that constructs a disease prediction model based on a time-blood glucose graph generated from the acquired near-infrared spectral data.

Abstract: The present invention relates to a composition for activating mitochondria which contains a chitooligosaccharide as an active constituent. The chitooligosaccharide can increase the activity of mitochondrial enzymes and increase the amount of mitochondrial DNA, and thus it can be suitably used as an active constituent in the composition for activating mitochondria.

Abstract: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-?-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.

Abstract: Disclosed is an anti-fatigue composition containing chitooligosaccharide as an active ingredient. The composition exhibits a fatigue recovery effect, and thus can be widely used in the health food or medical field.

Abstract: The present invention relates to a 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan compound which activates nutmeg-derived AMP-activated protein kinase (AMPK), and to a composition including same as active ingredients for preventing and treating metabolic syndromes such as obesity. More particularly, the present invention relates to an AMPK-activating compound comprising one of the 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan-based compounds produced by extracting Myristica fragrans with a solution of 30% or less of ethanol and separating and purifying the extracts using chromatography, as expressed in chemical formula 1 below, and to a composition comprising same as an active ingredient for preventing and treating metabolic syndrome caused by AMPK enzyme activation, such as obesity, diabetes, high cholesterol and cardiopulmonary diseases.

Abstract: The present invention relates to a composition containing a green tea extract as an active ingredient. The composition is effective in treating or preventing obesity and the like and can be beneficially employed in various ways in fields such as foodstuffs and medicine.

Abstract: The present invention relates to a composition for activating mitochondria which contains a chitooligosaccharide as an active constituent. The chitooligosaccharide can increase the activity of mitochondrial enzymes and increase the amount of mitochondrial DNA, and thus it can be suitably used as an active constituent in the composition for activating mitochondria.

Abstract: Disclosed herein is a composition for promoting AMPK activity, which comprises a chito-oligosaccharide as an active ingredient. The present composition affects the enzymes related to AMPK and lipid metabolism, and thus helps recovery from the condition lacking energy by various functions of controlling metabolism. Therefore, the present composition can enhance energy metabolism, thus making the composition effective for improving exercise capacity and reducing fatigue. The present composition can be used in the preparation of food or medicinal product as an endurance builder or for the prevention and improvement of fatigue.

Abstract: Disclosed herein is the use of a composition, containing isoflavone-containing soybean extract, L-carnitine, caffeine and arginine as active ingredients, for the treatment of obesity and diabetes. The disclosed composition contains isoflavone-containing soybean extract, carnitine, caffeine and arginine in the form of a mixture, and thus shows not only the effect of promoting lipolysis and fat burning, but also anti-obesity and anti-diabetic effects by increasing the expressions of adiponectin and Glut4 genes to restore insulin sensitivity.

Abstract: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-?-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.

Abstract: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-?-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.

Abstract: The downregulation of PRP 19 (precursor RNA processing 19) protein expression results in effectively reducing the expression of SCD1 (stearyl CoA desaturase-1), the key lipogenic enzyme, and its down-stream triacylglycerol synthesis enzymes, DGAT-1 (diacyglycerol acyltransferase-1) and GPAT (glycerol-phosphate acyltransferase), as well as the intracellular content of neutral lipids, the major target for treating obesity.

Abstract: The present invention relates to a composition for external application enhancing the skin absorption of the active components infused in the composition, more specifically relates to an external application having enhanced skin permeability of the active components by using protease stabilized by &bgr;-1,3-glucan branched with &bgr;-1,6-linkage as an agent for enhancing the skin permeability to weaken the wall properties of the corneous layer.